The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent

被引:28
作者
Baak, Jan P. A.
van Diest, Paul J.
Voorhorst, Feja J.
van der Wall, Elsken
Beex, Louk V. A. M.
Vermorken, Jan B.
Janssen, Emiel A. M.
Gudlaugsson, Einar
机构
[1] Stavanger Univ Hosp, Dept Pathol, N-4068 Stavanger, Norway
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] Univ Bergen, Gade Inst, N-5020 Bergen, Norway
[4] Free Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MC Amsterdam, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[6] Univ Antwerp Hosp, Antwerp, Belgium
关键词
D O I
10.1016/j.ejca.2006.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In lymph-node-negative invasive breast cancer patients < 55 years, the proliferation marker mitotic activity index (MAI) has previously been shown to be the strongest prognosticator. In studies without age definition, MAI was not strongly prognostic. We investigated the age dependency of the prognostic value of proliferation for distant metastasis-free (MFS) and overall cancer-related survival (OS) in 1004 histologically diagnosed T1-3N0M0 invasive breast cancers (n = 516, < 55 years; n = 322, 55-70 years; n = 166, > 70 years) without systemic adjuvant therapy and long follow-up (median: 108 months). The MAI decreases with age and the prognostic value of MAI varied by age group. For patients < 55 years, hazard ratios (HR) for MAI >= 10 versus < 10 for MFS and OS were 3.1 and 4.4, respectively (P < .0001 for both), but only 1.9 and 1.9 (P = .004 and .006) for patients aged 55-70 years, while over 70 years, MAI was not significant (P = .11). The prognostic value of proliferation was age-dependent. Prognostic breast cancer studies must clearly indicate the age group being studied. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:527 / 535
页数:9
相关论文
共 35 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study [J].
Amadori, D ;
Nanni, O ;
Marangolo, M ;
Pacini, P ;
Ravaioli, A ;
Rossi, A ;
Gambi, A ;
Catalano, G ;
Perroni, D ;
Scarpi, E ;
Giunchi, DC ;
Tienghi, A ;
Becciolini, A ;
Volpi, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3125-3134
[3]   Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer [J].
Andre, F ;
Khalil, A ;
Slimane, K ;
Massard, C ;
Mathieu, MC ;
Vignot, S ;
Assi, H ;
Delaloge, S ;
Spielmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2996-3000
[4]  
[Anonymous], 1981, HIST TYP BREAST TUM
[5]   Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers [J].
Baak, JPA ;
Colpaert, CGA ;
van Diest, PJ ;
Janssen, E ;
van Diermen, B ;
Albernaz, E ;
Vermeulen, PB ;
Van Marck, EA .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (14) :2093-2101
[6]   Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years [J].
Baak, JPA ;
van Diest, PJ ;
Voorhorst, FJ ;
van der Wall, E ;
Beex, LVM ;
Vermorken, JB ;
Janssen, EAM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5993-6001
[7]  
BAAK JPA, 1985, CANCER, V56, P374, DOI 10.1002/1097-0142(19850715)56:2<374::AID-CNCR2820560229>3.0.CO
[8]  
2-9
[9]   THE MULTICENTER MORPHOMETRIC MAMMARY-CARCINOMA PROJECT (MMMCP) - A NATIONWIDE PROSPECTIVE-STUDY ON REPRODUCIBILITY AND PROGNOSTIC POWER OF ROUTINE QUANTITATIVE ASSESSMENTS IN THE NETHERLANDS [J].
BAAK, JPA ;
VANDIEST, PJ ;
ARIENS, AT ;
VANBEEK, MWPM ;
BELLOT, SM ;
FIJNHEER, J ;
VANGORP, LHM ;
KWEE, WS ;
LOS, J ;
PETERSE, HC ;
RUITENBERG, HM ;
SCHAPERS, RFM ;
SCHIPPER, MEI ;
SOMSEN, JG .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (05) :664-670
[10]   IN SEARCH FOR THE BEST QUALITATIVE MICROSCOPICAL OR MORPHOMETRICAL PREDICTOR OF ESTROGEN-RECEPTOR IN BREAST-CANCER [J].
BAAK, JPA ;
PERSIJN, JP .
PATHOLOGY RESEARCH AND PRACTICE, 1984, 178 (04) :307-314